These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 35426547)

  • 21. The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines.
    Wei J; Hui AM
    Cancer Treat Rev; 2022 Jun; 107():102405. PubMed ID: 35576777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspectives and Prospects on mRNA Vaccine Development for COVID-19.
    Jin L; Han Z; Zhao P; Sun K
    Curr Med Chem; 2022; 29(23):3991-3996. PubMed ID: 35170403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research progress on the quality control of mRNA vaccines.
    Hu C; Bai Y; Liu J; Wang Y; He Q; Zhang X; Cheng F; Xu M; Mao Q; Liang Z
    Expert Rev Vaccines; 2024; 23(1):570-583. PubMed ID: 38733272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mRNA vaccines against infectious diseases and future direction.
    Aleem MT; Munir F; Shakoor A; Gao F
    Int Immunopharmacol; 2024 Jun; 135():112320. PubMed ID: 38788451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mRNA vaccine in cancer therapy: Current advance and future outlook.
    Li Y; Wang M; Peng X; Yang Y; Chen Q; Liu J; She Q; Tan J; Lou C; Liao Z; Li X
    Clin Transl Med; 2023 Aug; 13(8):e1384. PubMed ID: 37612832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules.
    Zhang J; Liu Y; Li C; Xiao Q; Zhang D; Chen Y; Rosenecker J; Ding X; Guan S
    Pharmaceutics; 2023 Aug; 15(9):. PubMed ID: 37765153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy.
    Jolly KJ; Zhang F
    Adv Pharmacol; 2024; 100():247-288. PubMed ID: 39034054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database.
    Musa HH; Musa TH
    Hum Vaccin Immunother; 2022 Nov; 18(6):2135927. PubMed ID: 36328513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic mRNAs Containing Minimalistic Untranslated Regions Are Highly Functional In Vitro and In Vivo.
    Mamaghani S; Penna RR; Frei J; Wyss C; Mellett M; Look T; Weiss T; Guenova E; Kündig TM; Lauchli S; Pascolo S
    Cells; 2024 Jul; 13(15):. PubMed ID: 39120273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.
    Chen P; Shi X; He W; Zhong G; Tang Y; Wang H; Zhang P
    Hum Vaccin Immunother; 2022 Dec; 18(1):2040330. PubMed ID: 35321627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines.
    Guo X; Liu D; Huang Y; Deng Y; Wang Y; Mao J; Zhou Y; Xiong Y; Gao X
    Virol J; 2023 Apr; 20(1):64. PubMed ID: 37029389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Current Landscape of mRNA Vaccines Against Viruses and Cancer-A Mini Review.
    Ladak RJ; He AJ; Huang YH; Ding Y
    Front Immunol; 2022; 13():885371. PubMed ID: 35603213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
    Pascolo S
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33572452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
    Ogura W; Ohtsuka K; Matsuura S; Okuyama T; Matsushima S; Yamasaki S; Miyagi H; Sekiguchi K; Ohnishi H; Watanabe T
    Viruses; 2022 May; 14(5):. PubMed ID: 35632698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequence-Optimized mRNA Vaccines Against Infectious Disease.
    Rauch S; Lutz J; Mühe J; Kowalczyk A; Schlake T; Heidenreich R
    Methods Mol Biol; 2024; 2786():183-203. PubMed ID: 38814395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections.
    Parums DV
    Med Sci Monit; 2021 May; 27():e932915. PubMed ID: 33942804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases.
    Yang L; Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():896958. PubMed ID: 35928814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.